KDM6A Loss

CI-VAR-00002495Explore in graph →CIViC 4310

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Myeloid Leukemia4
FLT3 ITD AND KDM6A Loss	Olaparib	Predictive	D	Supports Sensitivity Response	3	submitted	EID11035 FLT3-ITD positive AML cells with lower KDM6A expression showed sensitivity to olaparib. Open in CIViC	civic
KDM6A Loss	Olaparib	Predictive	D	Supports Sensitivity Response	3	submitted	EID11034 An array of KDM6 deficient AMP cells showed increased sensitivity to PARP inhibition. In a mouse model xenotransplant with a KDM6A loss of function AMP cell line increased susceptibility to PARP block… (full text at CIViC) Open in CIViC	civic
KDM6A Loss	Olaparib + VenetoclaxCombination	Predictive	D

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Bladder Neoplasm1
KDM6A Loss	EZH2 Inhibitor	Predictive	D	Supports Sensitivity Response	4	submitted	EID11749 In this study, an EZH2 inhibitor was tested for effectiveness against KDM6A-null cancer in mouse and patient-derived xenografts. The growth of KDM6A null tumours was significantly inhibited in the in … (full text at CIViC) PMID 28228601 · Ler et al., 2017 · Open in CIViC	civic

Malignant Bladder Neoplasm1

KDM6A Loss

EZH2 Inhibitor

Predictive

Supports Sensitivity Response

submitted

EID11749

In this study, an EZH2 inhibitor was tested for effectiveness against KDM6A-null cancer in mouse and patient-derived xenografts. The growth of KDM6A null tumours was significantly inhibited in the in … (full text at CIViC)

PMID 28228601 · Ler et al., 2017 · Open in CIViC

civic

Malignant Pancreatic Neoplasm1
KDM6A Loss	BET Inhibitor	Predictive	D	Supports Sensitivity Response	3	submitted	EID11750 In this study, sensitivity to BET domain inhibitors was tested in KDM6A-null pancreatic cancer cell lines. The BET inhibitor was reported to inhibit the growth of KDM6A null cell lines upon transplant… (full text at CIViC) PMID 29533787 · Andricovich et al., 2018 · Open in CIViC	civic

Malignant Pancreatic Neoplasm1

KDM6A Loss

BET Inhibitor

Predictive

Supports Sensitivity Response

submitted

EID11750

In this study, sensitivity to BET domain inhibitors was tested in KDM6A-null pancreatic cancer cell lines. The BET inhibitor was reported to inhibit the growth of KDM6A null cell lines upon transplant… (full text at CIViC)

PMID 29533787 · Andricovich et al., 2018 · Open in CIViC

civic